Rituximab therapy for hepatitis C virus‐associated cryoglobulinemic membranoproliferative glomerulonephritis

Membranoproliferative glomerulonephritis associated with mixed cryoglobulinemia is the most common form of kidney disease observed in relation to hepatitis C virus (HCV) infection. Rituximab, a monoclonal antibody against CD20, is an effective treatment for severe and/or refractory HCV‐related vascu...

Descripción completa

Detalles Bibliográficos
Autores principales: Koratala, Abhilash, Zeng, Xu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Clinical Images
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5799646/
https://www.ncbi.nlm.nih.gov/pubmed/29445495
http://dx.doi.org/10.1002/ccr3.1371
_version_ 1783298043365294080
author Koratala, Abhilash
Zeng, Xu
author_facet Koratala, Abhilash
Zeng, Xu
author_sort Koratala, Abhilash
collection PubMed
description Membranoproliferative glomerulonephritis associated with mixed cryoglobulinemia is the most common form of kidney disease observed in relation to hepatitis C virus (HCV) infection. Rituximab, a monoclonal antibody against CD20, is an effective treatment for severe and/or refractory HCV‐related vasculitis and may evade the need for dialysis as in our patient.
format Online
Article
Text
id pubmed-5799646
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-57996462018-02-14 Rituximab therapy for hepatitis C virus‐associated cryoglobulinemic membranoproliferative glomerulonephritis Koratala, Abhilash Zeng, Xu Clin Case Rep Clinical Images Membranoproliferative glomerulonephritis associated with mixed cryoglobulinemia is the most common form of kidney disease observed in relation to hepatitis C virus (HCV) infection. Rituximab, a monoclonal antibody against CD20, is an effective treatment for severe and/or refractory HCV‐related vasculitis and may evade the need for dialysis as in our patient. John Wiley and Sons Inc. 2018-01-04 /pmc/articles/PMC5799646/ /pubmed/29445495 http://dx.doi.org/10.1002/ccr3.1371 Text en © 2018 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd. This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial (http://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Clinical Images
Koratala, Abhilash
Zeng, Xu
Rituximab therapy for hepatitis C virus‐associated cryoglobulinemic membranoproliferative glomerulonephritis
title Rituximab therapy for hepatitis C virus‐associated cryoglobulinemic membranoproliferative glomerulonephritis
title_full Rituximab therapy for hepatitis C virus‐associated cryoglobulinemic membranoproliferative glomerulonephritis
title_fullStr Rituximab therapy for hepatitis C virus‐associated cryoglobulinemic membranoproliferative glomerulonephritis
title_full_unstemmed Rituximab therapy for hepatitis C virus‐associated cryoglobulinemic membranoproliferative glomerulonephritis
title_short Rituximab therapy for hepatitis C virus‐associated cryoglobulinemic membranoproliferative glomerulonephritis
title_sort rituximab therapy for hepatitis c virus‐associated cryoglobulinemic membranoproliferative glomerulonephritis
topic Clinical Images
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5799646/
https://www.ncbi.nlm.nih.gov/pubmed/29445495
http://dx.doi.org/10.1002/ccr3.1371
work_keys_str_mv AT koratalaabhilash rituximabtherapyforhepatitiscvirusassociatedcryoglobulinemicmembranoproliferativeglomerulonephritis
AT zengxu rituximabtherapyforhepatitiscvirusassociatedcryoglobulinemicmembranoproliferativeglomerulonephritis

Ejemplares similares